Posters & Papers
This presentation, given at the 2025 AAPS PharmSci Conference by Dawn Dufield, PhD, Scientific Officer of Mass Spectrometry at KCAS Bio, reviews Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. ADC_ARC Conjugates Presentation AAPS 2025_KCAS Bio…
Blogs
Drug discovery is an essential part of the drug development process. Researchers test candidates to identify those suitable for regulated animal studies and, ultimately, clinical trials. Bioanalytical discovery involves assessing a compound’s physiochemical properties,…
Posters & Papers
Discover in this poster presented by Ryan Darling at the AAPS National Biotechnology Conference 2025 on the use of a hybrid LC-MS/MS approach for the quantitation of total antibody TAb and intact Antibody Drug Conjugate (ADC). HybridLC-MSMSAssayforADCQuantitation_KCASBioDownload If you have any…
Posters & Papers
Discover in this poster presented by Bryan Parmentier at WRIB 2025, our work for the sponsor Lilly on the “Determination of Cisplatin in Human Plasma by LC-MS/MS using Hemoglobin to Overcome Matrix Effects“. Cisplatin In Human Plasma By LC-MS/MS | KCAS BioDownload If…
Blogs
ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to the…
Blogs
Antibody-drug conjugates (ADCs) have been conventionally developed for a wide range of oncological applications since the first ADC approval in 2000 by the FDA. Typically, an ADC consists of three main components: antibody, linker conjugate, and therapeutic drug (payload). The mechanism of an ADC involves the antibody binding to a specific…
Podcasts
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…
Blogs
Oligonucleotide therapeutics have recently gained popularity as noted by recent increases in regulatory approvals of oligonucleotides as drugs, novel liquid nanoparticle delivery approaches, and on-target specificity. In the development of bioanalytical assays, there are many challenging aspects to consider when quantitating oligonucleotides, such as non-specific binding, stability, efficient ionization, sequence…
November 15
- November 17
Along with a series of studies we plan to present related to our experiences with hybrid LC-MS/MS technology, KCAS will also be presenting on a study where we analyzed a compound that involved looking at urea in plasma and lung fluid (urea, of course, being a biomarker). Urea is endogenous…
Blogs
Dr. Sohrab Habibi Goudarzi – Senior Director of Pharma Discovery and R&D Services, Bryan Parmentier – Senior Principal Scientist of Pharma Method Development, and Yu-Hui (Ann) Fu -Principal Scientist of Pharma Regulatory, along with other scientists at KCAS Bioanalytical & Biomarker Services, coauthored with scientists at Gilead Sciences, Inc. in…
Blogs
Although bioanalysis is KCAS’ principal area of expertise, we are always considering how we can build around those capabilities to ensure that we can provide optimal service for our clients. Our current breadth of service enables us to provide a comprehensive approach during non-GLP pre-clinical studies where it is feasible…
Blogs
Although small molecules represent the majority of compounds in development as drug candidates, there is an increasing tendency to more complex molecular structures to address unmet molecular needs. This has been reflected in the…